Difficulty: Medium
Average Score: 89%
Practice
Monthly injections of palivizumab, a RSV-specific monoclonal antibody, initiated just before the onset of the RSV season confers some protection from severe RSV disease. Palivizumab is indicated for some infants under 2 years old with
Correct answer
B
Rationale
The correct answer is B) Very low birth weight. Palivizumab is indicated for some infants under 2 years old with certain risk factors, such as very low birth weight, to provide protection against severe respiratory syncytial virus (RSV) disease. Infants with very low birth weight are at higher risk for severe RSV infection due to their underdeveloped immune systems and respiratory systems.
Option A) Spasmodic croup is not an indication for palivizumab. Croup is typically caused by viruses other than RSV.
Option C) Cyanotic congenital heart disease is a risk factor for severe RSV infection, but it is not the indication specifically mentioned for palivizumab use in this scenario.
Option D) GERD (gastroesophageal reflux disease) is not a risk factor for severe RSV infection and is not an indication for palivizumab administration.
Educationally, it is crucial for healthcare providers, particularly nurses, to understand the appropriate use of medications like palivizumab to prevent severe respiratory illnesses in vulnerable pediatric populations. By knowing the specific indications for palivizumab, nurses can advocate for appropriate treatment and support families in protecting their infants from RSV-related complications. Understanding the rationale behind these indications is essential for providing safe and effective care to pediatric patients.
Option A) Spasmodic croup is not an indication for palivizumab. Croup is typically caused by viruses other than RSV.
Option C) Cyanotic congenital heart disease is a risk factor for severe RSV infection, but it is not the indication specifically mentioned for palivizumab use in this scenario.
Option D) GERD (gastroesophageal reflux disease) is not a risk factor for severe RSV infection and is not an indication for palivizumab administration.
Educationally, it is crucial for healthcare providers, particularly nurses, to understand the appropriate use of medications like palivizumab to prevent severe respiratory illnesses in vulnerable pediatric populations. By knowing the specific indications for palivizumab, nurses can advocate for appropriate treatment and support families in protecting their infants from RSV-related complications. Understanding the rationale behind these indications is essential for providing safe and effective care to pediatric patients.